{"entity":{"id":"nct07116577","kind":"trial","name":"Radiotherapy Combined QL1706, TAS-102 and Bevacizumab in mCRC","aka":[],"tldr":"A phase 2 trial of iparomlimab and tuvonralimab, trifluridine/tipiracil and bevacizumab (glioblastoma use) in colorectal cancer, run by Jinan Central Hospital, not yet recruiting.","summary":"Radiotherapy Combined QL1706, TAS-102 and Bevacizumab in mCRC is a phase 2, interventional study registered as NCT07116577 by Jinan Central Hospital, with a registry enrolment figure of 37 participants, started 2025-08-31 and due to reach its primary completion in 2027-08-31. Interventions recorded: Palliative radiotherapy; Iparomlimab and tuvonralimab; TAS-102; Bevacizumab. Conditions listed: mCRC. Primary outcome: ORR. Colorectal eligibility wording from the registry: \"* Histologically confirmed unresectable colorectal adenocarcinoma\". Sites: China. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07116577","url":"https://clinicaltrials.gov/study/NCT07116577"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer"],"sections":[],"technologies":["cytotoxic-chemotherapy","imrt-igrt"],"targets":[],"drugs":["iparomlimab-tuvonralimab","trifluridine-tipiracil","bevacizumab-glioma"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07116577","phase":"2","setting":"A Single-Arm, Exploratory Study of Palliative Radiotherapy Combined With Iparomlimab and Tuvonralimab, Trifluridine/Tipiracil (TAS-102), and Bevacizumab in Later-Line Treatment of Advanced Colorectal Cancer","sponsor":"Jinan Central Hospital","enrolled":37,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07116577/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"}],"drug":[{"id":"bevacizumab-glioma","kind":"drug","name":"Bevacizumab (glioblastoma use)","route":"/drugs/bevacizumab-glioma/"},{"id":"iparomlimab-tuvonralimab","kind":"drug","name":"Iparomlimab and tuvonralimab","route":"/drugs/iparomlimab-tuvonralimab/"},{"id":"trifluridine-tipiracil","kind":"drug","name":"Trifluridine/tipiracil","route":"/drugs/trifluridine-tipiracil/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}